{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8872","upperLimit":"0.9908","value":"0.9390"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Proportion of no Grade 3+ cardiac toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMC-A12 + Multi-agent intensive chemotherapy regimen.","id":"OG000","title":"IMC-A12"}],"paramType":"NUMBER","populationDescription":"18 participants were excluded because of ineligibility or insufficient information to assess feasibility.","reportingStatus":"POSTED","timeFrame":"From start to week 26 of therapy","title":"Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment","type":"PRIMARY","unitOfMeasure":"Proportion of Participants"}